Skip to main
DNTH

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc., a clinical-stage biotechnology company, demonstrates a strong positive outlook due to its strategic advancement in the clinical pipeline, particularly with the potential of Claseprubart, which is expected to exhibit greater potency compared to riliprubart. Financial projections indicate a significant potential appreciation in shares, with estimates suggesting a 25%-30% increase based on a favorable probability scenario and optimistic advancements in their trials. Additionally, the updated cash position forecast of approximately $514 million by year-end 2025 solidifies the company’s capacity for continued development, thereby bolstering investor confidence and supporting a market valuation increase.

Bears say

Dianthus Therapeutics Inc. may face significant financial challenges due to its reliance on securing adequate funding, which is critical for advancing its clinical pipeline. The potential inability to raise sufficient funds could hinder the company's progress in developing its next-generation complement therapeutic, Claseprubart, and other treatments. Furthermore, an unsuccessful interim scenario could exacerbate these issues, leading to increased uncertainty regarding the company's future prospects and operational viability.

DNTH has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 12 analysts, DNTH has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.